INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,993,063 | -13.5% | 441,410 | +5.1% | 0.02% | -10.0% |
| Q2 2023 | $26,582,137 | +43.2% | 419,806 | +22.3% | 0.02% | +33.3% |
| Q1 2023 | $18,559,513 | +3.3% | 343,377 | +1.1% | 0.02% | 0.0% |
| Q4 2022 | $17,974,912 | +21.6% | 339,662 | +6.9% | 0.02% | +15.4% |
| Q3 2022 | $14,787,000 | -18.9% | 317,795 | -0.5% | 0.01% | -13.3% |
| Q2 2022 | $18,226,000 | +56.2% | 319,299 | +67.5% | 0.02% | +87.5% |
| Q1 2022 | $11,666,000 | +2242.6% | 190,663 | +1905.5% | 0.01% | – |
| Q4 2021 | $498,000 | +55.1% | 9,507 | +10.3% | 0.00% | – |
| Q3 2021 | $321,000 | -0.6% | 8,621 | +8.9% | 0.00% | – |
| Q2 2021 | $323,000 | -65.9% | 7,918 | -87.9% | 0.00% | -100.0% |
| Q4 2017 | $946,000 | -8.2% | 65,330 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,031,000 | -45.7% | 65,330 | +33.6% | 0.00% | -50.0% |
| Q2 2016 | $1,898,000 | – | 48,896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |